- Annual report 2007/2008
-
Annual report 2008/2009
- 2008/2009 In brief
- President’s comments
- Hemtex share
- Presentation of operations
- Board of Directors’ report
- Income statements
- Balance sheets
- Changes in consolidated shareholders’ equity
- Changes in Parent Company shareholders’ equity
- Cash-flow statements
-
Notes
- Note 1 - Accounting principles
- Note 2 - Segment reporting
- Note 3 - Other operating income
- Note 4 - Employees and personnel costs
- Note 5 - Fees to auditors
- Note 6 - Depreciation/amortization of tangible and intangible fixed assets
- Note 7 - Exchange-rate differences that affected profits
- Note 8 - Net financial items
- Note 9 - Appropriations
- Note 10 - Taxes
- Note 11 - Earnings per share
- Note 12 - Intangible fixed assets
- Note 13 - Tangible fixed assets
- Note 14 - Financial fixed assets
- Note 15 - Deferred tax assets/deferred tax liabilities
- Note 16 - Prepaid expenses and accrued income
- Note 17 - Shareholders’ equity
- Note 18 - Untaxed reserves
- Note 19 - Liabilities to credit institutions
- Note 20 - Overdraft facilities
- Note 21 - Derivative held for hedging
- Note 22 - Accrued expenses and deferred income
- Note 23 - Pledged assets
- Note 24 - Contingent liabilities
- Note 25 - Leasing fees relating to operational leasing
- Note 26 - Adjustments for non-cash flow items
- Note 27 - Transactions not entailing payment
- Note 28 - Paid interest
- Note 29 - Acquisition of subsidiaries/operations
- Note 30 - Financial risks and risk policies
- Note 31 - Transactions with related parties
- Note 32 - Events after the closing date
- Note 33 - Important estimates and assessments
- Note 34 - Proposed dividend to shareholders
- Note 35 - Information about the Parent Company
- Note 36 - Definitions of key data
- Nine-year summary
- Proposed distribution of earnings
- Audit report
- Board of Directors
- Corporate Governance
- Management
- Hemtex stores
- Information about the AGM
- Annual reports archive
- Annual report 2009
- Annual Report 2010
- Annual Reports archive
Note 32 - Events after the closing date
New share issue completed
Hemtex’s new share issue was oversubscribed and the guarantee commitment that was secured did not need to be used. The new share issue contributed SEK 164 M before issue expenses. Hemtex’s new share issue was fully registered with the Swedish Companies Office on June 2, 2009, after which the total number of shares in the company amount to 41,072,360.
Offer from Hakon Invest AB
On April 28, 2009, Hakon Invest AB submitted a cash tender offer to the shareholders of Hemtex AB in compliance with the Swedish rules for mandatory takeover offers. Hakon Invest offered SEK 23 in cash per share together with an add-on premium of SEK 4 per share, which would be payable if Hakon Invest reached a shareholding exceeding 50% of the shares and votes in Hemtex AB. In a statement issued on June 11, 2009, the Board of Directors of Hemtex deemed Hakon Invest’s offer of SEK 23 per share to be inadequate since the offer did not reflect the Board’s perception of the company’s long-term potential. On June 18, 2009, Hakon Invest raised the consideration of the offer to SEK 27 in cash per share, with no possibility to receive any additional premium, and extended the acceptance period from June 22 to July 6. On June 23, 2009, Hakon Invest announced that the company, following a preliminary acceptance count, held 55.8% of the shares in Hemtex.